RNACCartesian Therapeutics, Inc.

$216M

Q2 2018 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$0-100.0% YoY

Gross Profit

$0

Operating Income

-$19M

Net Income

-$19M

EPS (Diluted)

$-25.22

QoQ Revenue Growth

NaN%

Cash Flow

Operating Cash Flow

-$17M

Free Cash Flow

-$17M

Stock-Based Comp.

$1M

Balance Sheet

Total Assets

$73M

Total Liabilities

$49M

Stockholders' Equity

$24M

Cash & Equivalents

$60M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$0	$26,000	-100.0%
Gross Profit	$0	$26,000	-100.0%
Operating Income	-$19M	-$16M	-18.3%
Net Income	-$19M	-$16M	-17.7%

RNAC Q2 2018 Earnings — Cartesian Therapeutics, Inc. Revenue & Financial Results | Market Cap Arena